Daily non-political popular news in brief.
Tiny tweezers and yeast help St. Jude show how cancer drug works
07-09-2007 · EurekAlert!The annoying bulges of an over-wound telephone cord that shorten its reach and limit a caller's motion help to explain why drugs called camptothecins are so effective in killing cancer cells, according to investigators at St. Jude Children's Research Hospital and Delft University of Technology.
Read more »
Keywords: tiny, tweezers, yeast, jude, show, cancer, drug, works, tweezer, work
« Previous | Next »
Similar news on "Tiny tweezers and yeast help St. Jude show how cancer drug works":
- Taxol bristle ball: a wrench in the works for cancer
09-12-2007 · EurekAlert!
Rice University chemists have discovered a way to load dozens of molecules of the anti-cancer drug Taxol onto tiny gold spheres. The result is a ball many times smaller than a living cell that literally bristles with the drug. Researchers hope to use the Taxol bristle ball to deliver large quantities of Taxol directly to cancer cells. The research will appear in the Sept. 19 issue of the Journal of the American Chemical Society.
Similar news · Read more »
- Early Phase II results show bosutinib safe, effective for CML
12-11-2007 · EurekAlert!
A new drug for chronic myelogenous leukemia works for patients who have developed resistance to frontline therapy and causes fewer side effects than other medications in its class, a research team led by scientists at the University of Texas M. D. Anderson Cancer Center reports at the 49th annual meeting of the American Society of Hematology.
Similar news · Read more »
- 2 drugs work better together than either alone against kidney cancer
07-30-2007 · EurekAlert!
A combination of two drugs works better than either drug alone for patients with renal cell carcinoma, the most common form of kidney cancer, according to a pilot study led by Duke University Comprehensive Cancer Center researchers.
Similar news · Read more »
- Leukemia drug turns mini-molecules up, cancer genes down
03-01-2007 · EurekAlert!
New research shows that a form of vitamin A used to treat acute promyelocytic leukemia induces changes in an unusual class of small molecules called microRNAs (miRNAs) in the leukemic cells. The study also shows that three of these miRNAs inhibit the action of two genes important for cancer development, helping to explain how the drug works.
Similar news · Read more »
- Tequila raw ingredient being developed into drug-carrier that targets colon diseases
03-27-2007 · EurekAlert!
Compounds derived from the blue agave, a fruit used to make tequila, show promise as a natural, more effective way to deliver drugs to the colon than conventional drug-carriers, according to chemists at the University of Guadalajara in Mexico. The discovery could lead to improved treatments for a variety of colon diseases, including ulcerative colitis, irritable bowel and cancer, they say. The research will be presented in March at the American Chemical Society national meeting.
Similar news · Read more »
- Translating form into function
07-01-2007 · EurekAlert!
In the last 40 years, scientists have perfected ways to determine the knot-like structure of enzymes, but they've been stumped trying to translate the structure into an understanding of function -- what the enzyme actually does in the body. This puzzle has hurt drug discovery, since many of the most successful drugs work by blocking enzyme action. Now, in an expedited article in Nature, researchers show that a solution to the puzzle is finally in sight.
Similar news · Read more »
- A new pharmaceutical drug that halts progress of metastatic kidney cancer
03-01-2007 · EurekAlert!
Research has shown the efficacy of a pharmaceutical drug known as sunitinib which halts progress of metastatic kidney cancer. The work was published recently in the prestigious international medical journal, the New England Journal of Medicine.
Similar news · Read more »
- Mice predict the effectiveness of orally taken drugs
11-01-2007 · EurekAlert!
More than half of all orally-prescribed medications are broken down in the intestine and liver by an enzyme known as CYP3A before reaching their site of action. Researchers from the Netherlands Cancer Institute have now developed a mouse model for predicting the loss in available drug due to first-pass metabolism by CYP3A, providing a tool to help predict whether drugs being developed will work effectively if given orally.
Similar news · Read more »
- 'Micro' livers could aid drug screening
11-19-2007 · Massachusetts Institute of Technology (MIT)
MIT researchers have devised a novel way to create tiny colonies of living human liver cells that model the full-sized organ. The work could reduce costs and allow better screening of new drugs that are potentially harmful to the liver.
Similar news · Read more »
- Cetuximab may prolong survival for head and neck cancer patients
01-18-2007 · EurekAlert!
Preliminary findings show adding the chemotherapy drug cetuximab (brand name Erbitux) to radiation therapy and chemotherapy may help some patients with head and neck cancer live longer, according to a study presented at the plenary session of the Multidisciplinary Head and Neck Cancer Symposium, co-sponsored by the American Society for Therapeutic Radiology and Oncology, the American Society for Clinical Oncology and the American Head and Neck Society.
Similar news · Read more »
